What is the recommended treatment regimen for severe asthma in an adult?

Treatment of Severe Asthma in Adults

For severe asthma in adults, the preferred treatment is high-dose inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA), with the addition of oral corticosteroids if needed, and consideration of omalizumab for patients with allergies. 1

Stepwise Treatment Algorithm for Severe Asthma

Step 5 (Severe Persistent Asthma - Initial Approach)

• Preferred regimen: High-dose ICS + LABA 1
• Add: Omalizumab (Xolair) for patients with documented allergic asthma 1
• All patients: Continue short-acting beta2-agonist as needed for quick relief

Step 6 (Most Severe - When Step 5 Fails)

• Preferred regimen: High-dose ICS + LABA + oral corticosteroids (daily or alternate-day dosing) 1, 2
• Continue: Omalizumab for allergic patients 1
• Dosing: Oral corticosteroids at 1-2 mg/kg/day, generally not exceeding 60 mg/day 2
• Critical principle: Make repeated attempts to reduce systemic corticosteroids and maintain control with high-dose inhaled corticosteroids 2

Before Escalating to Step 6

Always verify these factors first 1, 2:

1. Adherence: Confirm patient is actually taking medications as prescribed
2. Inhaler technique: Review and correct improper technique
3. Environmental control: Address ongoing allergen or irritant exposures
4. Comorbidities: Manage conditions that worsen asthma (GERD, rhinosinusitis, obesity)

Alternative Add-On Therapies (When Standard Approach Insufficient)

Before introducing oral corticosteroids in Step 6, consider trial of 1:

• High-dose ICS + LABA + leukotriene receptor antagonist, OR
• High-dose ICS + LABA + theophylline (requires serum level monitoring), OR
• High-dose ICS + LABA + zileuton (requires liver function monitoring)

Important caveat: These triple-therapy combinations have not been studied in clinical trials for severe asthma 1

Evidence Regarding Third Medication Addition

One study found no benefit for adding a leukotriene receptor antagonist to high-dose ICS + LABA in patients already on oral corticosteroids 2. This suggests that adding a third long-term controller to avoid systemic steroids is not supported by evidence 2.

Newer Biologic Options for Severe Asthma

While the NAEPP guidelines (2010) only mention omalizumab, more recent evidence supports additional biologics 3, 4:

For Severe Eosinophilic Asthma:

• Anti-IL-5 agents (mepolizumab, reslizumab): Use when blood eosinophils ≥150 cells/μL 3
• Benralizumab (anti-IL-5 receptor α): Use when blood eosinophils ≥300 cells/μL 5
• Dupilumab (anti-IL-4/13): Recommended for severe eosinophilic asthma and corticosteroid-dependent asthma regardless of eosinophil levels 5, 3

For Severe Allergic Asthma:

• Omalizumab (anti-IgE): Use when serum IgE >30 IU 5
• Consider specific cut-offs: eosinophils ≥260/μL and exhaled nitric oxide ≥19.5 ppb to identify greatest responders 3

Additional Adjunctive Therapies

Tiotropium (Long-Acting Muscarinic Antagonist)

• Suggested for adolescents and adults with severe uncontrolled asthma despite Step 5 therapy 3
• Can be added to ICS-LABA regimen 6

Chronic Macrolide Therapy

• Azithromycin 500 mg three times weekly for 48 weeks reduces exacerbations in adults 50-70 years with ongoing symptoms despite >80% adherence to high-dose ICS (>800 μg/day) and at least one exacerbation requiring oral steroids in past year 7
• Consider for persistently symptomatic patients on Step 5 therapy, irrespective of phenotype 3
• Warning: May increase macrolide-resistant bacteria in sputum 7

Critical Pitfalls to Avoid

1. Never use LABA as monotherapy - always combine with ICS 1
2. Do not add leukotriene receptor antagonist as third medication to ICS + LABA in severe asthma already requiring oral steroids - no proven benefit 2
3. Minimize oral corticosteroid exposure - use lowest effective dose and attempt dose reduction regularly 2
4. Monitor for corticosteroid adverse effects in patients on high-dose ICS or chronic oral steroids 8
5. Refer to asthma specialist - consultation is recommended for all patients with severe persistent asthma 2

Monitoring and Follow-Up

• Assess control regularly and step down therapy if asthma well-controlled for at least 3 months 1
• If using short-acting beta2-agonist >2 days/week for symptom relief (not exercise prevention), this indicates inadequate control requiring step-up 1
• For patients on biologics, trial therapy for minimum 6-12 months to assess efficacy 7